Lexology July 18, 2024
On 18 July 2024, Roche announced that FDA has accepted its supplemental BLA for Susvimo®, a refillable ocular implant containing a specialised formulation of ranibizumab, for the treatment of diabetic macular oedema (DME) and diabetic retinopathy (DR).
This follows the FDA’s approval of the relaunch of Susvimo® for nAMD earlier...